Introduction
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), the major receptor for oxidized low-density lipoprotein (oxLDL) in endothelial cells 1) , is a key molecule in the pathogenesis of atherosclerosis 2) . Basal expression of LOX-1 is very low and up-
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Clinical Examinations
The following information was collected from medical records of the stroke patients: height; weight; results of routine blood examinations including lipid profiles, high sensitive-C reactive protein (hs-CRP), medication for hypertension, dyslipidemia, and diabetes; and stroke severity assessed by National Institutes of Health Stroke Scale (NIHSS) scores on admission and stroke subtypes. Subtypes of ischemic stroke, such as atherothrombotic brain infarction (ABI; n 43), lacunar (n 56), cardioembolic (n 59), and other types (n 92), were diagnosed as previously described 8) . For controls, similar information was extracted from the Suita Study.
Morning blood samples after overnight fasting (within 3 days after onset of stroke for cases) were collected to be kept at 80°C until measurement of sLOX-1 levels. In all patients, serum lipids levels were immediately measured at the same in-hospital laboratory as previously described 8) . Serum hs-CRP levels were measured using an ultra-sensitive latex-enhanced immunoassay with an automatic analyzer (BN ProSpec System, Siemens, Munich, Germany). sLOX-1 levels were measured by ELISA using 2 monoclonal antibodies against LOX-1 as described previously 9) but using mouse anti-human LOX-1 monoclonal antibody (MAB1798, R&D, Minneapolis, Minnesota, USA) instead of TS92.
Aim
We aimed to cross-sectionally examine the serum sLOX-1 levels in acute stroke patients compared with age-and sex-matched healthy controls according to stroke subtype.
Methods
Subjects
We subsequently enrolled 377 patients with stroke (251 men and 126 women; 40 -79 years old), 250 with ischemic stroke and 127 with intracerebral hemorrhage (ICH), who were admitted to the National Cerebral and Cardiovascular Center (NCVC) within 3 days after the onset from August 2008 to August 2010.
As controls, we randomly selected age-and sexmatched subjects without a past history of cardiovascular disease according to stroke subtype. Controls were randomly selected from the participants of the Suita study, which is a community-based cohort study conducted by NCVC, ongoing since 1989. Control subjects were from among those who had visited NCVC for follow-up survey from April 2006 to December 2007. The details of the Suita study were previously described 7) . This study was approved by the Institutional Research and Ethics Committee of NCVC, Suita, Japan. Informed consent was obtained from all participants. subtype, which were compared with age-and sexmatched controls and adjusted for age, cigarette smoking, body mass index, hypertension, diabetes, and dyslipidemia. High sLOX-1 level was defined as 1177 ng/ L (corresponding to the 80th percentile of all stroke patients) or more. A p value of 0.05 was considered to indicate statistical significance.
Results
Median values of serum sLOX-1 in patients with acute stroke were significantly higher than those in
Statistical Analysis
All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, California, USA). Inter-quartile ranges of sLOX-1 levels were shown with associated p values using the Wilcoxon signed rank sum test for inter-group comparison. For other continuous variables, means and standard deviations were shown with p values using paired t -test. Proportions were compared between groups using McNemar's test. In addition, conditional and unconditional logistic regression analyses were used to calculate odds ratios and 95% confidence intervals for high sLOX-1 levels by each stroke artery as the onset of acute coronary syndrome; therefore, high levels of sLOX-1 in patients with ABI may indicate atherogenic reactions as the underlying mechanism for the onset of ABI.
In this study, more than 90% of patients with ICH had hypertension. Up-regulation of LOX-1 expression in the cortex of spontaneously hypertensive rats was implicated to induce neuronal apoptosis 13) . In contrast, the contribution of LOX-1 to hypertensive ICH has not been clarified. Colocalization of LOX-1 and matrix metalloproteinases were reported in a patient with ruptured and unruptured multiple dissections of the middle cerebral artery 14) , and extremely high sLOX-1 levels were shown to be present in patients with acute aortic dissection 15) . We reported that cultured bovine aortic endothelial cells and Chinese hamster ovary cells expressing bovine LOX-1 bound and phagocytosed aged red blood cells and dead cells, apart from oxLDL as a ligand for LOX-1 16) . In addition, the binding of LOX-1 ligands including oxLDL and CRP usually up-regulates the expression of LOX-1. These findings suggest that LOX-1 would bind red blood cells of ruptured hematoma in the brain tissues after the onset of ICH, causing the upregulation of sLOX-1 as well as LOX-1 expression in the present study.
The present study has several limitations. First, changes in sLOX-1 levels before and after the onset of stroke have not been examined because this is a crosssectional study. Second, variation in sLOX-1 levels could be large, and the power to estimate the differences may not be adequate because of the small sample size. Further examinations with a large number of cases are required to clarify the role of sLOX-1 in each type of ischemic stroke. Third, delay in blood sampling in the present study could underestimate the controls: 526 vs. 486 ng/L in ischemic stroke (p 0.009) and 720 vs. 513 ng/L in ICH (p 0.001) ( Table 1 ). In patients with ABI, the median sLOX-1 levels were significantly higher than those in controls: 641 vs. 496 ng/L (p 0.02) ( Table 2 ). There were no significant differences between patients and controls in sLOX-1 levels in the other subtypes of ischemic stroke. Ischemic stroke and ICH were associated with high levels of sLOX-1 after adjusting for age, cigarette smoking, body mass index, hypertension, diabetes, and dyslipidemia (odds ratio, 3.80 in ischemic stroke; 5.97 in ICH) ( Table 3) .
Discussion
This is the first study to be shown that serum sLOX-1 concentrations in patients with acute stroke were higher than age-and sex-matched controls.
LOX-1 is primarily expressed in endothelial cells, and several studies have revealed that it is also expressed in macrophages and smooth muscle cells 10) . Cellular uptake of oxLDL via LOX-1 by macrophage and smooth muscle cells was demonstrated to be involved in atherogenic reactions, such as apoptosis, and expression of matrix metalloproteinases 4, 11) . Elevated levels of sLOX-1 are considered to reflect the increased expression of LOX-1, and it was suggested that high levels of sLOX-1 could be a biomarker for vulnerability of atherosclerotic plaques 6) . Peak levels of sLOX-1 in patients with acute coronary syndrome were reported to occur within one day after admission to hospital 6) . In the present study, significant increases in serum sLOX-1 levels were observed in patients with ABI compared with those in controls. Ogata et al 12) showed that the rupture of an atheromatous plaque can cause thrombotic occlusion of a stenotic internal carotid levels of sLOX-1 because peak levels of sLOX-1 in acute coronary syndrome were reported within one day after admission.
Conclusion
The present study showed that acute stroke was associated with high levels of sLOX-1 compared with age-and sex-matched controls. High levels of sLOX-1 can be useful as biomarkers for acute stroke. Further studies are required to clarify the contribution of sLOX-1 to the pathogenesis of stroke.
